Screener
BridgeBio Pharma BBIO Share Buybacks
Share Buybacks at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Issuance costs and discounts associated with 2033 Notes | (12,796) | — |
| Proceeds from issuance of 2031 Notes | — | 575,000 |
| Issuance costs and discounts associated with 2031 Notes | — | (12,034) |
| Repurchase of common stock | (82,500) | (48,276) |
| Repayment of term loans | — | (459,000) |
| Repayments of deferred royalty obligations (3) | (11,293) | (144) |
| Proceeds from common stock issuances under ESPP | 5,466 | 3,237 |
| Proceeds from stock option exercises, net of repurchases | 22,589 | 2,521 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's share buybacks?
- BridgeBio Pharma (BBIO) reported share buybacks of $82.5M in Q1 2026.
- How has BridgeBio Pharma's share buybacks changed year-over-year?
- BridgeBio Pharma's share buybacks increased by 70.9% year-over-year, from $48.28M to $82.5M.
- What is the long-term trend for BridgeBio Pharma's share buybacks?
- Over 3 years (2021 to 2024), BridgeBio Pharma's share buybacks has grown at a -100.0% compound annual growth rate (CAGR), from $200M to $0.
- What does share buybacks mean?
- Cash used to buy back the company's own shares on the open market or through structured programs, reducing shares outstanding.
Ask your AI about BridgeBio Pharma's share buybacks.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude